Sana Biotechnology, Inc. Other Noncash Income (Expense)
Sana Biotechnology, Inc. (SANA) reported Other Noncash Income (Expense) of $4.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-10
- Sana Biotechnology, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was $2.26M, a 10.58% decline year-over-year.
- Sana Biotechnology, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was $2.62M, a 20.06% decline year-over-year.
- Sana Biotechnology, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was $3.10M, a 3.88% decline year-over-year.
- Sana Biotechnology, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was $2.08M, a 30.48% decline year-over-year.
- Sana Biotechnology, Inc. other noncash income (expense) for fiscal 2025 was $10.98M, a 0.92% decline from fiscal 2024.
- Sana Biotechnology, Inc. other noncash income (expense) for fiscal 2024 was $11.08M, a 16.78% decline from fiscal 2023.
- Sana Biotechnology, Inc. other noncash income (expense) for fiscal 2023 was $13.31M, a 43.11% increase from fiscal 2022.
- Sana Biotechnology, Inc. other noncash income (expense) for fiscal 2022 was $9.30M, a 202.41% increase from fiscal 2021.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.87M 10-Q · filed 2026-08-10 | $7.97M derived: sum of 3 quarters · filed 2026-08-10 | $10.05M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $2.62M 10-Q · filed 2026-05-11 | $5.71M derived: sum of 2 quarters · filed 2026-05-11 | $7.80M derived: sum of 3 quarters · filed 2026-05-11 | $10.32M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $5.18M derived: sum of 2 quarters · filed 2026-03-03 | $7.71M derived: sum of 3 quarters · filed 2026-08-10 | $10.98M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.61M derived: sum of 2 quarters · filed 2026-08-10 | $7.88M 10-Q · filed 2025-11-06 | $11.10M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.79M 10-Q · filed 2026-08-10 | $9.02M derived: sum of 3 quarters · filed 2026-08-10 | $12.01M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $3.27M 10-Q · filed 2026-05-11 | $6.50M derived: sum of 2 quarters · filed 2026-05-11 | $9.49M derived: sum of 3 quarters · filed 2026-05-11 | $9.47M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.22M derived: sum of 2 quarters · filed 2026-03-03 | $6.20M derived: sum of 3 quarters · filed 2026-03-03 | $11.08M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.97M derived: sum of 2 quarters · filed 2025-11-06 | $7.85M 10-Q · filed 2025-11-06 | $11.20M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $4.86M 10-Q · filed 2025-08-11 | $8.21M derived: sum of 3 quarters · filed 2026-03-03 | $12.08M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-03-31 | $4.88M 10-Q · filed 2025-05-08 | $8.23M derived: sum of 2 quarters · filed 2026-03-03 | $12.10M derived: sum of 3 quarters · filed 2026-03-03 | $15.28M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2023-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.22M derived: sum of 2 quarters · filed 2026-03-03 | $10.40M derived: sum of 3 quarters · filed 2026-03-03 | $13.31M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $7.05M derived: sum of 2 quarters · filed 2024-11-08 | $9.96M 10-Q · filed 2024-11-08 | $12.58M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-06-30 | $3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.09M 10-Q · filed 2024-08-08 | $8.70M derived: sum of 3 quarters · filed 2025-03-17 | $11.66M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-03-31 | $2.91M 10-Q · filed 2024-05-08 | $5.53M derived: sum of 2 quarters · filed 2025-03-17 | $8.49M derived: sum of 3 quarters · filed 2025-03-17 | $10.78M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2022-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $5.58M derived: sum of 2 quarters · filed 2025-03-17 | $7.87M derived: sum of 3 quarters · filed 2025-03-17 | $9.30M 10-K · filed 2025-03-17 | |
| 2022-09-30 | $2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $5.25M derived: sum of 2 quarters · filed 2023-11-08 | $6.69M 10-Q · filed 2023-11-08 | $7.51M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.73M 10-Q · filed 2023-08-03 | $4.55M derived: sum of 3 quarters · filed 2024-02-29 | $4.78M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $1.44M 10-Q · filed 2023-05-08 | $2.26M derived: sum of 2 quarters · filed 2024-02-29 | $2.49M derived: sum of 3 quarters · filed 2024-02-29 | $3.50M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $821.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.05M derived: sum of 2 quarters · filed 2024-02-29 | $2.06M derived: sum of 3 quarters · filed 2024-02-29 | $3.08M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $233.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $1.24M derived: sum of 2 quarters · filed 2022-11-02 | $2.25M 10-Q · filed 2022-11-02 | $2.84M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2021-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.02M 10-Q · filed 2022-08-04 | $2.61M derived: sum of 3 quarters · filed 2023-03-16 | $2.28M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2021-03-31 | $1.01M 10-Q · filed 2022-05-10 | $1.60M derived: sum of 2 quarters · filed 2023-03-16 | $1.27M derived: sum of 3 quarters · filed 2023-03-16 | $1.13M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2020-12-31 | $586.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $260.00K derived: sum of 2 quarters · filed 2023-03-16 | $117.00K derived: sum of 3 quarters · filed 2023-03-16 | -$233.00K 10-K · filed 2023-03-16 | $1.30M 10-K · filed 2022-03-16 |
| 2020-09-30 | -$326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$469.00K derived: sum of 2 quarters · filed 2021-11-08 | -$819.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | -$143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$493.00K 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | -$350.00K 10-Q · filed 2021-05-05 | ||||
| 2019-12-31 | $592.00K 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |